Search Medical Condition
Please enter condition
Please choose location

Congestive Heart Failure Clinical Trials

A listing of Congestive Heart Failure medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (513) clinical trials

Quartet Lead and Resynchronization Therapy Options III (QUARTO III)

The primary endpoint of the study is to measure prospectively at 6 months the percentage of responder* patients implanted with a Quartet LV quadripolar lead and with the MultiPoint Pacing feature activated compared with No Pacing at baseline. *A positive CRT response is defined as an improvement of more than ...

Phase N/A

Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support

This time point was chosen because the bleeding events are maximal within the first 3 months after implantation. Adult patients > 18 years who need a CF-LVAD due to advanced heart failure. Functional To determine the potential indication of Wilfactin in the field of CF-LVAD and avoid widespread use and ...

Phase

HeartMate 3 ELEVATE

The purpose of this post-market registry is to collect data and evaluate the real-world experience of the HeartMate 3 Left Ventricular Assist System (HM3 LVAS) in a post-approval setting.

Phase N/A

MultiPoint Pacing Mapping Study

The purpose of this study is to characterize left ventricular acute hemodynamic and electrical responses during cardiac resynchronization therapy (CRT) with different Multipoint Pacing (MPP) settings, and assess the relationship between electrical activation patterns and hemodynamic measurements during these pacing settings.

Phase N/A

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

This study is designed as a prospective, randomized, multi-center trial. Data will be collected at enrollment, baseline, implant procedure, patient classification, 6 months and 12 months of follow-up. During the 6-month visit, the patient's response to CRT will be evaluated according to LVESV reduction. Patients with an LVESV reduction of ...

Phase N/A

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized ...

Phase

LifeVest Trends Validation Protocol

This is a multi-center validation study of heart failure patients wearing the LifeVest WCD modified to collect data on body position, activity, heart rate, 6-minute walk test, and a health survey in order to evaluate data accuracy and patient interactions with the device.

Phase N/A

Aquaresis Utility for Hyponatremic Acute Heart Failure Study

Hyponatremia is a common finding in acute heart failure (HF) patients and is associated with worse prognosis. In addition to its prognostic value, hyponatremia may have importance during the acute management of HF. We've recently shown that acute or chronic hyponatremia, especially <130 mEq/L, was associated with higher loop diuretic ...

Phase

Validation of the ApneaScan Algorithm in Sleep Disordered Breathing

72 patients with heart failure with reduced ejection fraction (HFREF) who have been selected to receive an Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy Pacemaker or Defibrillator (CRT-P/D) will undergo pre-implant assessment with an echocardiogram, B-type Natriuretic Peptide (BNP) level, 6 minute walk test, Minnesota living with heart failure and ...

Phase N/A

Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5 VAD System in Patients Awaiting Heart Transplantation

The HeartAssist 5 VAD System is intended for use as a bridge to heart transplantation and will be compared to the HeartMate II and HVAD devices. Patients that meet the study criteria will be randomized 1:1 to either the HeartAssist 5 VAD System (treatment group) or control group (HeartMate II ...

Phase N/A